Independent and not affiliated with the FDA, MHRA, ISPE, PDA, or any agency. Get the appgoutham@madhadi.com
madhadi.comData Integrity & GxP Quality
Browse all topics → Articles Templates & Procedures Learning paths GlossaryScenariosToolsRegulatory ReferencesLearning PathsTopics About Start here
Matrix Plug-and-play starting point Quality Assurance

Matrix: 21 CFR Part 4 Streamlined-Provision Mapping

A plug-and-play matrix mapping the added provisions under 21 CFR 4.4 to the procedure that satisfies each, the evidence, the applicability decision, and the owner, for both drug-base and device-base combination products, with a filled specimen and the regulations it satisfies.

Document type: Matrix

Read and copy the template below into your own quality system. It is a generic starting point for your own internal use, provided as is, with no warranty; see the Terms and License. Adopting it does not by itself create compliance.

This is a ready-to-use mapping matrix. It pins each provision added under 21 CFR 4.4 to the procedure that satisfies it, the evidence that demonstrates it, the applicability decision with rationale, and the accountable owner. It supports the combination product quality plan. Replace every <<FILL: ...>> placeholder, use the table that matches your base, and route it through document control. A worked filled specimen follows. Verify each cited regulation against the current source before you rely on it.

Control header

FieldEntry
Document number<<FILL: MX-ID>>
Product<<FILL>>
Base operating system<<FILL: 211 base OR 820/QMSR base>>
Linked quality plan<<FILL: QP number>>
Version / date / owner<<FILL>>

Table A: Drug/biologic base, device provisions added (21 CFR 4.4(b)(1))

Use this table if your base is 21 CFR 210/211.

ProvisionSectionWhat it must demonstrateProcedureEvidence / recordApplicable (Y/N + rationale)Owner
Management responsibility820.20Quality policy and objectives, organization, management representative, management review covering device scope<<FILL>><<FILL>><<FILL>><<FILL>>
Design controls820.30Design plan, inputs, outputs, review, verification, validation (incl. human factors), transfer, changes, DHF<<FILL>><<FILL: DHF>><<FILL>><<FILL>>
Purchasing controls820.50Device supplier evaluation, purchasing data, supplier agreements<<FILL>><<FILL>><<FILL>><<FILL>>
CAPA820.100Capture of device failure modes, investigation, action, effectiveness, management awareness<<FILL>><<FILL>><<FILL>><<FILL>>
Installation820.170Installation and inspection instructions and records, where applicable<<FILL>><<FILL>><<FILL: often N/A>><<FILL>>
Servicing820.200Servicing procedures and records, where servicing is a specified requirement<<FILL>><<FILL>><<FILL: often N/A>><<FILL>>

Table B: Device base, drug provisions added (21 CFR 4.4(b)(2))

Use this table if your base is 21 CFR Part 820 / QMSR.

ProvisionSectionWhat it must demonstrateProcedureEvidence / recordApplicable (Y/N + rationale)Owner
Component/container/closure testing211.84Sampling and testing of incoming drug components, with approval or rejection before use<<FILL>><<FILL>><<FILL>><<FILL>>
Calculation of yield211.103Actual and theoretical yield at appropriate phases<<FILL>><<FILL>><<FILL>><<FILL>>
Tamper-evident packaging211.132Tamper-evident packaging for OTC drug products<<FILL>><<FILL>><<FILL>><<FILL>>
Expiration dating211.137Scientifically justified expiration dating supported by stability<<FILL>><<FILL>><<FILL>><<FILL>>
Testing and release211.165Batch testing for identity, strength, conformance before release<<FILL>><<FILL>><<FILL>><<FILL>>
Stability testing211.166Written stability program with intervals, conditions, sound sampling<<FILL>><<FILL>><<FILL>><<FILL>>
Special testing211.167Sterility, pyrogen, or other special tests where required<<FILL>><<FILL>><<FILL>><<FILL>>
Reserve samples211.170Retention of reserve samples for required periods<<FILL>><<FILL>><<FILL>><<FILL>>

Acceptance criteria

  • Every applicable added provision maps to a named procedure and a real evidence record.
  • Every N/A carries a written rationale.
  • The base matches the quality plan, and only the relevant table is used.
  • The matrix is approved by QA and kept current as procedures change.

References

21 CFR Part 4, 4.4(b)(1) and 4.4(b)(2); 21 CFR Parts 210/211; 21 CFR Part 820 / QMSR; ISO 13485:2016.

Confirm the current version and clause numbers before issue.


Filled specimen

Drug-base case for an example prefilled syringe (drug-led). Illustrative.

ProvisionSectionProcedureEvidenceApplicableOwner
Management responsibility820.20Quality manual, management review SOP extended to device scopeManagement review minutesYesSite quality head
Design controls820.30SOP-DC-001 plus syringe DHF; HF validation per IEC 62366-1DHF, HF study reportYesDevice engineering
Purchasing controls820.50Supplier qualification SOP, device criteriaSupplier audit, agreementYesSupplier quality
CAPA820.100CAPA SOP, scope expanded to delivery malfunction and use errorCAPA recordsYesQuality systems
Installation820.170N/A: patient-administered, not installedDocumented rationaleN/AQuality
Servicing820.200N/A: single-use disposableDocumented rationaleN/AQuality

This is the artifact that turns “we comply with Part 211” into a defensible demonstration that the device provisions were each addressed.

Common inspection findings this matrix prevents

  • A provision named in the plan but with no procedure or evidence behind it.
  • An N/A with no rationale.
  • Both base tables filled in, signaling the team ran two full systems instead of the streamlined approach.

How to adapt this matrix

  1. Set your document number and link the quality plan.
  2. Keep only the table that matches your base; delete the other.
  3. Map each applicable provision to a real procedure and evidence record.
  4. Give a rationale for each N/A and have QA approve.
Use madhadi.com as an app Full screen, works offline, one tap from your home screen.